Hematocrit on TRT: The Definitive Guide

What is hematocrit, and why does it matter on TRT?

Hematocrit is the share of your blood made up of red blood cells. A result of 45% means red cells take up 45% of a blood sample's volume, and the liquid part (plasma) makes up most of the rest. Testosterone therapy raises hematocrit in most men, and hematocrit is one of the main safety checks guidelines use to decide whether a TRT dose needs changing. [20], [2], [13]

Red blood cells carry oxygen, so a modest rise is usually harmless and can even correct anemia (too few red cells). The concern is that blood with a very high share of red cells is thicker, and in people who do not take testosterone, a higher hematocrit goes with more blood clots. [21], [22]

When red cells climb above the normal range, doctors call it erythrocytosis, or secondary polycythemia. "Secondary" means the cause, here testosterone, sits outside the bone marrow. It is a different condition from polycythemia vera, a bone marrow disease with its own thresholds and treatment. [23], [24]

Hematocrit comes from a standard blood count, usually beside hemoglobin, the oxygen-carrying protein inside red cells. Labs report it as a percentage (45%) or a fraction in liters per liter (0.45 L/L). Normal ranges differ by lab: MedlinePlus gives 37–48% for men, and one UK National Health Service (NHS) laboratory uses 0.40–0.52 L/L (40–52%). Compare your result with your own lab's range. [20], [25], [26]

Hematocrit on TRT: the key numbers

This table shows the hematocrit lines in every major clinical guideline, both before starting treatment and during it. The numbers are what each document says, checked in September 2026.

[3], [13], [14], [27], [28], [29], [4], [5], [6], [30], [31], [32], [7], [33], [34]

Most bodies act at 54%: the AUA, the Endocrine Society, the EAU, the BSSM, the ICSM and the EAA, and the large TRAVERSE safety trial used the same line. The exceptions are the VA, which adjusts the dose above 51%, the UK Society for Endocrinology, which acts above 50%, and the CUA, which acts at 55%. Before treatment starts, most bodies become cautious at 48–50%, and the AUA above 50%. [3], [4], [5], [6], [35]

Doserly

Where guidelines draw the hematocrit line on TRT

On-treatment hematocrit (%) at which each body acts.

Each bar runs from 46% (left) to 56% (right); the shaded part is 48–50%, where most guidelines take care before starting.

Society for Endocrinology (UK, 2022)

Above 50% (0.50 L/L)

VA (US, January 2026)

Above 51%: adjust the dose · above 54%: stop

AUA (US, 2018, reconfirmed 2024)

54% or higher

Endocrine Society (2018)

Above 54%

EAU (Europe, 2026)

Above 54% (summary table: 54% or higher)

BSSM (UK, 2023)

Above 54%

ICSM (2024)

Keep below 54%

EAA (Europe, 2020)

Above 54%

CUA (Canada, 2021)

55% or higher, if it persists

Product labels (US, UK, Canada)

No number: labels say “elevated”

No trial has tested which line prevents clots or heart events.

Why do guidelines disagree?

Because no trial has tested which line prevents clots or heart problems. Each number is an expert judgment, and no trial has compared outcomes between men kept below 50%, 52% or 54% on testosterone. [16], [36]

The lower numbers you may see online come from other conditions:

• 45% is the treatment target for polycythemia vera. In a trial of 365 people with that marrow disease, keeping hematocrit below 45% cut heart deaths and major clots to 2.7%, compared with 9.8% at 45–50%. That result applies to polycythemia vera, not to TRT. [37]
• 49% is part of the diagnostic criteria for polycythemia vera in men, used together with bone marrow and gene tests. On its own it does not diagnose anything. [24]
• Below 0.55 L/L (55%) is the target the British Society for Haematology suggests for unexplained erythrocytosis, a target its own authors call "arbitrary". The same guideline sets no testosterone-specific target. [23]

How do the units work?

Hematocrit appears as a percentage (54%) or as liters of red cells per liter of blood (0.54 L/L); both mean the same. Hemoglobin appears in grams per deciliter or grams per liter: 18.0 g/dL is 180 g/L. A Canadian blood-donor study treated a hemoglobin of 180 g/L as equal to a hematocrit of 54%, but that is an approximation, so compare hematocrit with hematocrit where you can. [26], [38]

Guidelines also tie hematocrit decisions to your testosterone level, which labs report in ng/dL (US) or nmol/L (most other countries). TRAVERSE, for example, adjusted the gel dose to keep testosterone between 350 and 750 ng/dL (about 12 to 26 nmol/L). The testosterone unit converter switches between the two, and the TRT blood work guide explains when to draw each test. [39]

Why does testosterone raise hematocrit?

Testosterone tells the body to make more red blood cells in two ways: it frees up iron for new cells, and it resets the body's sense of how many red cells are "enough". Both effects are measured in people. [41], [42]

• More iron for red cells. Hepcidin is a hormone made by the liver that controls how much iron reaches the blood. In a study of 109 healthy young and older men given testosterone injections at research doses, hepcidin fell within a week, more so in older men, and the size of the drop at weeks 4 and 8 predicted how far hematocrit rose. The same pattern appeared in a placebo-controlled trial of 34 men with type 2 diabetes and low testosterone: hepcidin fell by 28% and hematocrit rose to 45.3% on average. [41], [43]
• A new "normal" for red cells. Erythropoietin (EPO) is the kidney hormone that tells the bone marrow to make red cells. In a 6-month trial of older men using testosterone gel, EPO rose early and was not switched off even though hemoglobin was higher, as if the body now accepted a higher red-cell level as normal. Ferritin, a measure of stored iron, fell as the iron was used. [42]
• Not through DHT. Testosterone is partly converted to dihydrotestosterone (DHT). In a 12-month trial in 60 older men, blocking that conversion with finasteride did not stop the rise: testosterone injections raised red cells by 9% and hematocrit by 4%, and cut hepcidin by 57%, either way. [44]
• In mice, testosterone switched down the liver's hepcidin gene and switched up the kidney's EPO gene, matching what the human studies suggest. [45]

Why do dose and form matter so much?

More testosterone means a bigger rise. In trials of healthy men given weekly enanthate injections at research doses (not treatment protocols), hematocrit rose in a straight line with the dose, and more in older men than in young men. [46], [47]

The level reached matters too, not just the dose written on the prescription. In 158 men on long-term testosterone pellets, a higher testosterone level just before the next implant (the trough) strongly predicted a hematocrit above 50%, and each extra year of age added about 10% to the odds. [9] Injections at usual doses also tend to push testosterone higher than other forms: in a randomized trial, cypionate injections raised testosterone by an average of 511 ng/dL, against 283 ng/dL for nasal gel. [48]

What else pushes hematocrit up?

Anything that lowers the oxygen reaching your tissues can add to the push, because the kidneys answer low oxygen with more EPO. Smoking, lung disease and living at altitude are the common examples, which is why the Endocrine Society allows a baseline of up to 50% at high altitude and the ICSM advises extra care there. [20], [49], [13], [28]

Some things raise the reading without adding red cells at all. When plasma shrinks, for example from dehydration or the first days at altitude, the same number of red cells takes up a larger share of the sample. On the first day at 2,500 m, plasma volume fell by about 6% and hematocrit rose by about 1.5 points in lowland visitors. [12], [20]

What does the research show?

Testosterone raised hematocrit in trials of nearly every form, most with enanthate or cypionate injections and oral undecanoate. How often it passes 54% varies widely between studies, from about 1 in 100 men to more than 1 in 5, depending on the form, dose, age of the men and length of follow-up. [8], [50], [51]

How much does hematocrit rise on TRT?

About 3 percentage points on average, with a wide spread between people.

The share passing 54% varies so much because the studies differ: long-acting injections in T4DM, gel with active dose control in TRAVERSE, older men in the Testosterone Trials, and different follow-up lengths. A 2025 systematic review of drug-caused erythrocytosis found rates as high as 66.7% in some groups of men on prescription testosterone, and higher risk with injections, higher doses and older age. [36]

Which forms of testosterone raise hematocrit the most?

In pooled trials, enanthate or cypionate injections and oral undecanoate raised it most and patches least; in a direct trial, nasal gel caused no significant change. A network meta-analysis of 29 placebo-controlled trials (3,393 men) estimated these average rises compared with placebo:

[8]

Only the difference between enanthate or cypionate injections and patches was statistically clear; the others overlapped. [8]

Doserly

How much each form raised hematocrit

Average rise compared with placebo, in percentage points (network meta-analysis of 29 trials, 3,393 men).

Bars run from 0 to 9 points; the thin line is the 95% range.

Oral testosterone undecanoate

+4.3 points (95% range 0.7–8.0)

Enanthate or cypionate injections

+4.0 points (95% range 2.9–5.1)

Gel

+3.0 points (95% range 1.8–4.3)

Undecanoate injections (long-acting)

+1.6 points (95% range 0.3–3.0)

Patch

+1.4 points (95% range 0.2–2.6)

The ranges overlap: only injections versus patches differed clearly.

Direct comparisons point the same way:

• Nasal gel versus injections. In a 4-month randomized trial, cypionate 200 mg injected every 2 weeks raised average hematocrit from 42.7% to 46.6%, while nasal testosterone (Natesto) caused no significant change. A third of the men did not finish. [48]
• Matched clinic records. In 78 matched men, hematocrit rose 4.4 points on cypionate injections, 1.7 on pellets and fell 0.8 on nasal gel. [57]
• Clinic records over 3 years. Hematocrit above 50% occurred in 66.7% of men on injections, 35.1% on pellets and 12.8% on gels, although the injection group was younger and the groups were not randomized. [58]
• Pellets. In 97 men, average hematocrit rose from 43.9% to 46.1% after pellet implants, and men who started lower rose more. [59]

The long-acting undecanoate injection is where the evidence conflicts. The meta-analysis put its average rise low (1.6 points), yet in a prospective registry, hematocrit passed 50% in 69 of 304 men starting undecanoate injections against 25 of 498 starting gel after about 6 months, and T4DM, which used the same injection, saw 22% pass 54%. Treat the low average with caution. (A large safety study that relied on doctors reporting side effects listed raised hematocrit in fewer than 1%, but that counts reports, not measurements.) [8], [60], [51], [61]

How fast does hematocrit rise, and how fast does it fall?

It rises over the first 3 to 12 months, and it falls back over about 3 months once testosterone stops.

• Rise. In a 6-month trial of testosterone gel in older men, hematocrit rose 3.59 points by month 3, when it peaked, and was still 2.96 points up at month 6. A review of treatment time courses puts the rise in red cells at about 3 months, with the peak at 9–12 months. In the single-clinic records, 46% of the men whose hematocrit passed 0.46 L/L peaked within the first year. [42], [62], [55]
• Later rises happen too. In one urology practice, the 37 men who had both sleep apnea and a hematocrit of 52% or more reached that level a median of 3 years after starting TRT. In the single-clinic records, the other 54% of men whose hematocrit passed 0.46 L/L peaked after the first year. A normal result in the first year does not rule out a later rise. [10], [55]
• Fall. In the gel trial, hemoglobin and hematocrit were back to normal 3 months after the men stopped. Among men who had used anabolic steroids outside medical care, hematocrit also returned to its starting level within 3 months of the end of a cycle. [42], [63]

Doserly

When hematocrit changes, study by study

On treatment

1. About 3 months

   Gel trial in older men: peak rise of 3.59 points. A review of treatment studies: the rise shows by about 3 months.

2. 6 months

   Same gel trial: still 2.96 points up.

3. 9–12 months

   Review of treatment studies: peak.

4. First year

   Single-clinic records: 46% of men whose hematocrit passed 0.46 L/L peaked in year one.

5. Median 3 years

   One urology practice, men with sleep apnea: median time to reach 52%.

After stopping or pausing

1. 3 months after stopping

   Same gel trial: back to normal.

2. 3-month pause

   Randomized trial in trans men with high hematocrit: down 3.5 points on average.

Each point comes from one study; no curve is drawn between them, and later rises can still happen.

Who is most likely to get a high hematocrit?

The same few factors come up across studies:

• A higher dose or testosterone level, cypionate or enanthate injections, and older age (see why dose and form matter). [46], [9], [8]
• A higher starting hematocrit and a higher body weight. Both predicted erythrocytosis in the single-clinic records. [55]
• Sleep apnea. In 474 men on TRT at one urology practice, 13.1% reached 52%, and men with obstructive sleep apnea had about twice the odds (adjusted odds ratio 2.09). [10] Sleep apnea on its own rarely causes erythrocytosis: in a sleep clinic study of 1,604 people, only 1.6% had it, and low oxygen levels, smoking, alcohol and testosterone use mattered more than apnea severity. [49], [64]
• Smoking. In 1,073 trans men on testosterone, smoking doubled the odds of a hematocrit above 0.50 L/L (odds ratio 2.2); a higher body mass index (odds ratio 3.7), lung conditions (2.5) and undecanoate injections (2.9) also raised the odds. These figures come from trans men, because the evidence in men with low testosterone is thinner; in 158 men on pellets, smoking showed a similar but uncertain effect. [56], [9]
• SGLT2 inhibitors for diabetes. See medicines that raise hematocrit. [11]

Is high hematocrit on TRT dangerous?

Nobody knows for sure. High hematocrit on TRT has been linked with more clots and heart events in records studies, but no trial has shown that it causes them, or that lowering it prevents them. That uncertainty is why guidelines set cautious lines rather than evidence-tested ones. [17], [16]

What points toward harm?

• Men on TRT. In a large US health-records study (cohort study), 5,842 men whose hematocrit reached 52% or more on testosterone were matched with similar men whose hematocrit stayed lower. In the first year, heart attacks, strokes or blood clots occurred in 5.15% of the high-hematocrit group and 3.87% of the others (odds ratio 1.35). As absolute risks, that is about 5 in 100 men against about 4 in 100. Men on testosterone without a high hematocrit did not have more events than untreated men with low testosterone. Records studies cannot rule out other differences between the groups. [17]
• People not on testosterone. In a Norwegian population study of 26,108 people followed for a median of 12.5 years (447 clots), each 5-point rise in hematocrit went with a 25% higher risk of a clot in a vein (venous thromboembolism). In the Framingham study, the top fifth of hematocrit values went with more heart disease and death over 34 years. [22], [65]
• Genetics. In UK Biobank, men whose genes predict higher testosterone had more blood clots, but that study did not test whether hematocrit explained the link. [66]

What points the other way?

• TRAVERSE. Among men with anemia in TRAVERSE, the rise in hematocrit on testosterone was not linked with heart attacks, strokes or cardiovascular death (hazard ratio 0.97, with a likely range of 0.92 to 1.02) or clots (0.94, range 0.84 to 1.05). This analysis covered only men who started with anemia, on gel, with the dose lowered above 54%, so it does not show that high hematocrit is harmless. [21]
• Clot meta-analysis. Pooled randomized trials did not find a clear rise in venous clots with testosterone (odds ratio 1.42, with an uncertainty range from 0.22 to 9.03, too wide to settle the question). [67]
• Trans men. In one clinic, clots occurred in 0.9% of people on testosterone, and 80% of those had erythrocytosis, but without a comparison group this cannot show cause. [68]

What did TRAVERSE show about heart safety overall?

TRAVERSE is the largest trial of testosterone and heart safety, so it matters here even though it did not study hematocrit directly. Heart attack, stroke or cardiovascular death occurred in 7.0% of men on testosterone gel and 7.3% on placebo (hazard ratio 0.96), which met the trial's safety goal. Some problems were more common on testosterone: atrial fibrillation 3.5% vs 2.4%, acute kidney injury 2.3% vs 1.5%, and pulmonary embolism 0.9% vs 0.5%. [39], [32], [69]

Its limits matter: it tested only a daily gel, which the Endocrine Society says causes high hematocrit less often than injections; men used it for an average of 21.7 months; about 61% stopped their study gel early; and it enrolled men already at high heart risk. [39], [13], [69] The TRT and heart health guide covers the trial in full.

Who should be especially cautious?

• Men who already start near the line. A hematocrit of 48–50% or more before treatment is a reason to look for a cause first under most guidelines. [13], [14], [3]
• Men with untreated sleep apnea, lung disease or low oxygen levels, smokers, and men who live at altitude. These raise hematocrit on their own or add to the rise. The Endocrine Society and the VA list untreated severe sleep apnea as a reason not to start. [10], [56], [13], [4]
• Men with a history of blood clots or an inherited clotting disorder (thrombophilia). The Endocrine Society and the VA list thrombophilia as a reason not to start, the VA also lists a past clot without a clear trigger, and the EAU lists a family history of clots as a reason for caution. [13], [4], [14]
• Men taking SGLT2 inhibitors (see the next question). [11]
• Men with a known blood disorder such as polycythemia vera, which needs a hematologist's care. [23]
• Men who donate blood often, because of iron loss (see blood donation). [15]
• Drug-tested athletes. Testosterone is prohibited in sport at all times. [19]
• Under-18s. Testosterone for teenagers belongs only in specialist care.
• Women. This guide is written for men. Testosterone for women uses different doses and products; see testosterone therapy for women.

Which medicines and supplements affect hematocrit?

• SGLT2 inhibitors (such as empagliflozin and dapagliflozin, diabetes and heart medicines). These raise hematocrit on their own: on the US labels, median hematocrit rose 2.8% on empagliflozin while it fell 1.3% on placebo, and mean hematocrit rose 2.30% on dapagliflozin against a 0.33% fall on placebo. In 53,971 US veterans with diabetes, men taking both an SGLT2 inhibitor and testosterone had about 2.5 times the odds of a hematocrit above 54% compared with testosterone alone (adjusted odds ratio 2.49). In a second cohort of 5,235 men with diabetes starting TRT, 113 of 3,146 SGLT2 users (3.6%) passed 54%, against 28 of 2,089 non-users (1.3%). UK testosterone labels now warn about the combination, and an EU safety review in September 2025 recommended adding the warning to all testosterone products. [70], [71], [11], [72], [40], [73]
• Anabolic steroids raise hematocrit too: in men using them outside medical care, it rose by an average of 0.03 L/L (3 points) during a cycle. [63]
• Supplements sold to "thin the blood" have not been tested in men on TRT, and some carry their own risks. See what supplements can and cannot do.

Bring a complete list of what you take, including supplements, to a pharmacist or prescriber. Checked September 2026.

Is testosterone legal, and is it allowed in sport?

Checked September 2026. Rules differ by country and change often.

• United States. Testosterone and its esters are Schedule III controlled substances, prescription only. No proposal to change that has been published. [18]
• United Kingdom. Testosterone is a Class C controlled drug, in Schedule 4 Part II of the Misuse of Drugs Regulations. [74]
• Canada. Testosterone is a Schedule IV controlled substance. [75]
• Australia. Testosterone is a Schedule 4 prescription-only medicine. [76]
• Sport. The World Anti-Doping Agency (WADA) prohibits testosterone at all times, and its 2027 list, published in September 2026, keeps the ban. [19], [77]

What do guidelines say to do about high hematocrit?

Guidelines first check whether the testosterone level is too high, then lower the dose, pause treatment or switch to a form that raises hematocrit less, and look for sleep apnea or low oxygen. Removing blood is a secondary option in some guidelines and discouraged by others. This section describes the choices clinicians weigh; it is not a personal plan. [3], [13], [14], [5]

[3], [13], [14], [27], [29], [4], [5], [6], [31]

Is pausing TRT better than lowering the dose?

For bringing the number down quickly, yes, in the one randomized comparison, which was in trans men. Among 43 trans men with hematocrit of 50% or more on cypionate, stopping for 3 months lowered hematocrit by 3.5 points, while halving the dose to 100 mg every 2 weeks lowered it by 0.8 points. In a records study from the same group, a 3-month pause took average hematocrit from 51.57% to 46.34%. [78], [80] The Endocrine Society and the EAA describe stopping until hematocrit falls, then restarting at a lower dose. Symptoms of low testosterone can come back during a pause; the stopping TRT guide covers what happens when testosterone stops. [13], [29]

Do smaller, more frequent injections lower hematocrit?

Possibly, but no study has tested it directly. The only comparison is observational: among men starting below 54%, 1 of 102 men on 100 mg weekly passed 54%, compared with 4 of 51 men on 200 mg every 2 weeks. The weekly total was the same, but the men were not randomized. [50] Going the other way, lengthening cypionate injections from every 14 to every 28 days did not significantly lower hematocrit in trans men. [80] No study has kept the weekly dose exactly the same and simply split it into more injections, so claims that splitting "fixes" hematocrit go beyond the evidence. The TRT dosage guide covers splitting schedules, and the TRT dose calculator shows how a split changes the amount per injection.

Is subcutaneous safer than intramuscular for hematocrit?

The evidence conflicts. In 234 men, weekly subcutaneous enanthate by autoinjector (Xyosted) was linked with lower hematocrit than weekly intramuscular (into a muscle) cypionate at similar testosterone levels, but the route, the ester and the device all differed and the men were not randomized. A 2026 conference abstract of 100 first-time TRT users found no difference in hematocrit between subcutaneous and intramuscular injections. No trial has switched men from one route to the other and measured hematocrit. [81], [82] The injection guide compares the two routes in more detail.

Does treating sleep apnea lower hematocrit?

A little, based on studies outside TRT. In people with obstructive sleep apnea, one night on CPAP (a machine that keeps the airway open with air pressure) lowered hematocrit from 44.0% to 42.4% in one study and from 45.4% to 43.1% in another. Part of that quick change may reflect fluid shifts rather than fewer red cells, and no study has tested CPAP in men on TRT. [79], [83], [10]

Is therapeutic phlebotomy recommended?

Only as a secondary option (see the table above). A 2024 review concluded that evidence for the benefit or safety of phlebotomy for testosterone-induced erythrocytosis is lacking, and warned that the iron loss it causes might itself activate pathways linked with clotting. Australia's blood service does not accept men with secondary polycythaemia for therapeutic donation and says there is no evidence to support it. [16], [84] See blood donation for what one donation does.

How do blood donation, water and lab timing affect hematocrit?

Does donating blood lower hematocrit?

Yes, for several weeks, but it also drains iron, and there is no evidence that it prevents clots or heart problems on TRT. In a randomized trial in healthy, trained men, one 470 mL donation lowered hematocrit by up to 11% of its starting value and halved ferritin, and repeat donations 3 months apart added up. [15], [16]

In men on TRT, donation often does not keep hemoglobin down for long. At Canadian Blood Services, 39 men on TRT had a hemoglobin of 180 g/L or more (about a 54% hematocrit) at 25% of their visits, and 12 of 27 repeat donors (44%) were still that high at later donations. [38] In US blood centers, donors on TRT had higher average hemoglobin than other donors (17.8 vs 15.6 g/dL). [85]

Can you donate blood while on TRT?

Checked September 2026. Each blood service sets its own rules, and they change.

• United States. Federal rules set only minimum levels for male donors (hemoglobin at least 13.0 g/dL or hematocrit at least 39%) and allow whole blood no more than once every 8 weeks, or a double red-cell donation every 16 weeks. The American Red Cross allows whole blood every 56 days and caps donor hemoglobin at 20 g/dL; its eligibility list has no testosterone entry. Vitalant says people who need blood draws for polycythemia caused by TRT can book a regular donation if they are eligible and do not need it more often than every 56 days. [86], [87], [88], [89], [90]
• Canada. Canadian Blood Services says donors taking hormone medicine can give if otherwise eligible, with 56 days between donations for men; Héma-Québec also uses 56 days for men. [91], [92], [93]
• United Kingdom. Men wait at least 12 weeks between whole-blood donations. Check NHS Blood and Transplant's eligibility pages for its current rules on testosterone before booking. [94]
• Australia. Lifeblood accepts donors whose testosterone is prescribed by an Australian doctor, checks hemoglobin before each donation because testosterone can push it above the accepted range, and allows whole blood every 12 weeks. [95], [96]

Therapeutic phlebotomy is different: blood removed on a prescriber's order to treat a condition, which US rules allow more often than these intervals. In the US, blood collected this way must be labeled with the donor's condition unless an approved exception applies. If you need blood removed more often than a normal donation allows, ask your prescriber and the blood service about it. At one US blood center, therapeutic phlebotomies for men on TRT rose to 239 a year before the center stopped offering them; afterwards, 32% of those men kept giving blood as regular volunteer donors. [87], [97]

Does frequent donation cause low iron?

Yes. Iron stores take months to refill: after a 500 mL donation, ferritin had still not recovered after 168 days in donors not given iron. In a trial of 45,263 UK donors, giving blood more often led to lower hemoglobin and ferritin and more donation-related symptoms, including tiredness. [98], [99] Low iron can also make hematocrit look lower than the red-cell count, because iron-poor red cells are smaller, and hematocrit depends on both the number and the size of the cells. [100] Tiredness is not always the iron, though: in iron-deficient donors without anemia, intravenous iron did not improve average fatigue scores. [101] See the iron supplement guide.

Can drinking more water or exercise lower hematocrit?

They change the reading, not the number of red cells. Dehydration shrinks plasma and pushes the reading up, so being well hydrated before a blood test gives a fairer result. In a small study, doubling water intake for a week lowered hematocrit by diluting the blood. Endurance training expands plasma, and 7 weeks of interval running lowered resting hematocrit in young men. Neither removes red cells. [20], [102], [103]

Do grapefruit, nattokinase, IP6 or aspirin lower hematocrit?

We found no study testing any of them in men with testosterone-related erythrocytosis.

• Grapefruit. The only study is a 1988 diet study of 36 people, not on TRT, with no comparison group. Grapefruit also changes how some medicines work, so check your medicine leaflets first. [104], [105]
• Nattokinase. A supplement enzyme sold to "thin" blood. It has no hematocrit data, and one man taking it with aspirin had a bleed in the brain. See the nattokinase guide. [106]
• IP6 (phytate). It blocks iron absorption from food in human studies, but no study has measured hematocrit. [107]
• Aspirin. No study has tested aspirin for testosterone-related erythrocytosis. It is a medicine with bleeding risks and a decision for your prescriber.

Does the timing of the blood test change the result?

A little. Hematocrit follows a daily rhythm, rising and falling by about 1 point (0.01 L/L) over the day. Fingerstick readings do not match a venous blood count: at the high end they read higher than the venous result. Dehydration raises the reading. [108], [109], [12] We found no study measuring how hematocrit changes between the peak and trough of a single injection cycle. A repeat venous test drawn under the same conditions (similar time of day, well hydrated) is the fairest comparison with the last one.

What do people on TRT report about hematocrit?

Public forums are full of men who have just seen one high hematocrit result, and of men who have spent years trying to keep it down. The threads below are recent public Reddit discussions, read with their replies; they show what people experience, not how often it happens.

What does a first high result usually look like?

Usually a number, not a symptom. Many posters feel well and are worried only by the lab report: one man in his 40s on 100 mg a week felt "completely fine" at 56% despite giving blood every 3 months, and another in his 40s felt better than he had in years at 52.2%, with ferritin low, while his doctor proposed cutting his dose from 100 to 60 mg a week. [110], [111] Clinicians' responses in these threads vary widely, from continuing the same dose and rechecking in 4 months at 0.51 L/L to pausing treatment. [112], [113]

Does a repeat test change the picture?

Often. One man whose result was 58% two weeks after donating, on a morning when he had drunk no water, reported 48% on a hydrated retest; another went from 56% to 51% on a retest his doctor ordered after he rehydrated, and a third, whose reading jumped to 53.7% during weeks of inactivity after surgery, was back near 49.5% on a later retest. [114], [113], [115] Others saw no change: one man's reading stayed at 0.51 L/L on two tests, one after drinking a liter of water beforehand. [112]

What do people report after giving blood?

Mixed results, and iron comes up again and again. One man's hematocrit fell from 51% to 43.4% nine days after a donation. [116] Another saw no drop at all three to four days after giving 450 mL, although his earlier test had been six weeks before the donation, while his ferritin fell from 149 to 107. [117] A man in his 50s described one donation taking him from 57% to 52%, only for it to climb back within about three weeks while his ferritin fell from 40 to 23 and he "felt like death". [118]

Several men describe a cycle of feeling worse as their counts climb and better about a week after donating; one stopped TRT after nearly a year of it. [119] Another felt weak, lightheaded and anxious for more than a week after a donation he later decided had not been needed. [120] Long-running accounts end with ferritin in single digits and constant fatigue. [121], [122]

What happened after lowering the dose, pausing or switching?

Results varied, and changes often took months. One man cut from 150 to 100 mg a week and found his hematocrit higher three months later (52.6% to 54.7%). [123] Another dropped from 200 to 140 mg a week, gave blood and split his injections, and hematocrit fell only from 53.6% to 52.1% while his testosterone fell from about 1,200 to 370 ng/dL and he felt much worse. [124] Eight weeks off treatment took one man from 0.54 to 0.51 L/L. [125] A man whose hematocrit went from 40% to 50% in two months on gel stopped it and measured 48% two weeks later. [126]

Some posts credit other changes, but each one changed several things at once. One man reported a fall from 56.5% to 49% in two months after starting a blood-pressure medicine and more cardio together, after a long list of supplements had not helped. [127] Another reported 55.0% falling to 49.2% over four weeks of daily grapefruit juice, but he had also just given blood and switched from injections to gel. [128]

Sleep apnea, altitude and other medicines come up in most long threads: men finding sleep apnea only after hematocrit rose, or booking a sleep study because they snore. [118], [129] One man with no TRT saw hematocrit rise from 48% to 51.5% in two months on enclomiphene, which raised his own testosterone. [130]

What gets in the way of giving blood?

Blood services turned men away for hemoglobin above their limit (19.2 and 20 g/dL in one case, in a man living at about 5,000 feet), for taking finasteride, or for weight-loss medicines, and one man could not find a local service that would accept his prescriber's phlebotomy order. [131], [132], [126], [133] One thread describes drawing blood at home into collection tubes; most replies steered people toward donation or clinician-performed phlebotomy instead. [134]

Are serious problems reported?

Some posts describe serious events, but selected accounts cannot show how often they happen or what caused them. One woman described her husband, on 100 mg a week for five years, having a cardiac event while his hematocrit was in range (48.3%) but his ferritin was 15 after six donations over three years; he also had a high inherited cholesterol marker (lipoprotein(a)) and was being checked for bleeding in the gut, and his doctors had not found the cause. [135] Posts describing chest discomfort or breathlessness drew replies urging prompt medical assessment. [136]

How can you judge a hematocrit story?

Ask: Was the sample drawn from a vein, in the morning, well hydrated? What was hematocrit before TRT? What was the testosterone level, not only the dose? How long ago was the last donation, and what was ferritin? Were sleep apnea, altitude, smoking, weight-loss or diabetes medicines, hCG or other hormones part of the picture? And what did the next test show?

These selected discussions show what people experience and the questions research has not answered. They are not a survey of all men on TRT, a success rate or a substitute for the studies above.

What should you track?

Hematocrit and hemoglobin before starting, at about 3–6 months, at 12 months, then yearly, with more frequent checks on some products and for men at higher risk. Use this summary to prepare questions for your prescriber; it is not a personal testing plan. [13], [14]

[13], [27], [7], [54], [10], [98], [11]

A single result is one point on a line. Because the time of day, hydration and even the type of sample move the reading, a trend of venous results drawn under similar conditions says more than any one number. The TRT blood work guide covers when to draw each test, and the testosterone level visualizer shows how injection frequency changes the peaks and troughs of testosterone itself. [108], [109]

Common questions about hematocrit on TRT

Is a hematocrit of 52% bad on TRT?

It is above many labs' normal range but below the line most guidelines act on (54%); the VA adjusts the dose above 51% and the Society for Endocrinology acts above 50%. In one records study, men who reached 52% had slightly more heart and clot events in their first year, without proof of cause. It is a reason to review the trend, the testosterone level and possible causes with your prescriber. [4], [5], [17] See the key numbers.

Should you stop TRT if your hematocrit is high?

Not necessarily for good. Above 54%, the Endocrine Society, the EAA and the EAU describe stopping or adjusting until it falls, then restarting at a lower dose; the AUA lowers the dose or pauses, and the BSSM lowers the dose or switches preparation. Stopping lowers hematocrit faster than a dose cut, but symptoms of low testosterone can return. [13], [29], [14], [3], [27], [78] See what guidelines do.

How long does it take for hematocrit to come down?

About 3 months after stopping testosterone. In a gel trial, hematocrit was back to normal 3 months after the men stopped, and in trans men a 3-month pause lowered it by 3.5 points on average. A dose cut works more slowly. A blood donation lowers it for a few weeks, until the body replaces the cells. [42], [78], [15] See how fast it falls.

Is hemoglobin the same as hematocrit?

No, but they move together. Hemoglobin is the oxygen-carrying protein inside red cells (g/dL or g/L); hematocrit is the share of blood volume taken up by red cells (%). Both come from the same blood count. The "multiply hemoglobin by three" rule you may see online has no primary source, so use the hematocrit your lab reports. [26], [20] See the units.

Does high hematocrit on TRT mean I have polycythemia vera?

Usually not. Polycythemia vera is a bone marrow disease diagnosed with marrow and gene tests, not from hematocrit alone. When hematocrit rises on testosterone, testosterone is the usual cause; the AUA suggests a hematologist review when the testosterone level is low or normal, because then another cause is more likely. [24], [23], [3] See what hematocrit is.

Can I lower hematocrit without giving blood?

Guidelines mostly do. Their first steps are checking the testosterone level, lowering the dose, pausing, switching to a form that raises hematocrit less, and treating sleep apnea. Drinking water and exercise change the reading but not the red-cell count, and no supplement has been tested for this. [3], [13], [8], [102] See the practical questions.

Glossary

Plain explanations of the medical, lab and research terms used in this guide. Underlined terms in the text link here.

Absolute risk

The share of people who have an event, such as 5.15 out of every 100 men. It is easier to judge than a relative risk, which only says how much higher one group's risk is than another's.

Anemia

Too few red blood cells or too little hemoglobin. Testosterone therapy can correct some anemia in men with low testosterone.

Cohort study (records study)

A study that follows a group of people, or looks back at their records, without assigning treatments. It can show links but not prove that one thing caused another.

Conference abstract

A short summary of a study presented at a medical meeting. It has usually not been fully peer reviewed, so it is weaker evidence than a published paper.

Controlled trial

A study that compares people who receive a treatment with a similar group who do not, often receiving a placebo instead. Randomly assigning people to each group makes the comparison fairer.

CPAP

Continuous positive airway pressure: a bedside machine that blows air through a mask to keep the airway open during sleep. It is the standard treatment for obstructive sleep apnea.

EPO (erythropoietin)

A hormone made mainly by the kidneys that tells the bone marrow to make red blood cells. The body makes more when oxygen is low.

Erythrocytosis (secondary polycythemia)

Too many red blood cells, shown by a high hematocrit or hemoglobin. On TRT it is called secondary because the cause, testosterone, is outside the bone marrow.

Ferritin

A protein that stores iron. Its blood level is the usual measure of iron stores, and it falls after blood donation and early in testosterone therapy.

Clinical guideline

Recommendations written by a medical society or health system, based on its review of the evidence and expert judgment. Different guidelines can reach different conclusions.

Hazard ratio

A measure comparing how often an event happens over time in two groups. A hazard ratio of 1 means no difference; 0.96 means about 4% lower in the first group.

Hematocrit

The share of the blood made up of red blood cells. Testosterone therapy can raise it, which is why it is checked.

Hematologist

A doctor who specializes in blood and bone marrow disorders.

Hemoglobin

The iron-containing protein inside red blood cells that carries oxygen. It is measured in grams per deciliter (g/dL) or grams per liter (g/L): 18.0 g/dL equals 180 g/L.

Hepcidin

A hormone made by the liver that controls how much iron enters the blood. Testosterone lowers it, making more iron available for new red cells.

Intramuscular (IM)

Injected into a muscle. Most testosterone cypionate and enanthate is given this way.

Product label (prescribing information)

The official document approved by a medicines regulator for a product, describing its approved uses, doses, warnings and monitoring. In the UK it is called the summary of product characteristics.

L/L (liters per liter)

A way of writing hematocrit as a fraction instead of a percentage. 0.54 L/L is the same as 54%.

Meta-analysis and systematic review

A systematic review gathers all studies on a question in a planned way. A meta-analysis combines their results statistically. A network meta-analysis compares several treatments at once, even ones never tested head to head.

Odds ratio

A measure comparing the odds of an outcome in two groups. An odds ratio of 2 means roughly twice the odds; 1 means no difference.

Therapeutic phlebotomy (venesection)

Removing blood on purpose to lower red cells or iron, usually about 500 mL at a time. A blood donation removes a similar amount.

Placebo

A dummy treatment with no active ingredient, used as a comparison in studies.

Plasma

The liquid part of the blood. When plasma shrinks, for example with dehydration, hematocrit reads higher even though the red cells have not changed.

Polycythemia vera

A bone marrow disease, usually caused by a gene change, in which the marrow makes too many red cells on its own. It has its own diagnostic tests and treatment targets and is different from testosterone-related erythrocytosis.

SGLT2 inhibitor

A group of diabetes, heart and kidney medicines, such as empagliflozin (Jardiance) and dapagliflozin (Farxiga), that make the kidneys remove sugar in urine. They raise hematocrit on their own.

Obstructive sleep apnea

Repeated blocking of the airway during sleep, causing pauses in breathing and drops in oxygen. Loud snoring and daytime sleepiness are common signs.

Subcutaneous (SC)

Injected into the fatty layer just under the skin. Xyosted is given this way, and some prescribers use this route for other testosterone injections.

Thrombophilia

An inherited or acquired tendency to form blood clots more easily than normal.

Transdermal

Absorbed through the skin, as with testosterone gels and patches.

Trough level

The lowest blood level of a medicine, just before the next dose or implant.

TRT (testosterone replacement therapy)

Prescribed testosterone, by injection, gel or other forms, for men with low testosterone.

Venous thromboembolism (VTE)

A blood clot in a vein, usually in the leg (deep vein thrombosis), which can travel to the lungs (pulmonary embolism).

WADA

The World Anti-Doping Agency, which publishes the list of substances banned in sport. Testosterone is prohibited at all times.

How this guide was researched

This guide is built from a thorough review of the sources cited throughout it: clinical guidelines from 11 medical bodies, product labels from several countries, published clinical trials and studies, blood-service rules and regulatory documents. We also reviewed public online forums where men on TRT describe their own hematocrit results.

The guide cites 136 sources, including 56 original studies in people, 12 clinical guidelines and position statements, and 27 public community discussions. Each type of source answers a different question. Guidelines and labels show what clinicians are told to do. Trials and studies show what was measured. Personal accounts show what individual people experienced. Every numbered citation links to its entry below, labeled by source type.

How this guide was made

Research and drafting were AI-assisted. Every cited source was checked against the original, and the guide was reviewed and edited by Doserly before publication. It has not had an independent clinical review, and Doserly does not currently have medical reviewers. Doserly makes a medication and health-tracking app and runs Doserly Academy, both of which are promoted in this guide. Read our editorial policy for how guides are researched, updated and corrected.

This guide is for educational purposes. It summarizes what the reviewed sources report so the research is easier to understand; it is not medical advice. For a deeper dive, or to check any point for yourself, go straight to the cited sources.

Explore the sources